CompletedPhase 4NCT00444379

Anti-Retrovirals for Kaposi's Sarcoma

Studying Kaposi sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of California, San Francisco
Principal Investigator
Dr. Jeffrey N Martin, MD, MPH
University of California, San Francisco
Intervention
Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir(drug)
Enrollment
224 enrolled
Eligibility
18 years · All sexes
Timeline
2007 – 2012

Study locations (1)

Collaborators

National Institutes of Health (NIH) · Gilead Sciences · Abbott · Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00444379 on ClinicalTrials.gov

Other trials for Kaposi sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Kaposi sarcoma →

← Back to all trials